Sakar Healthcare
435.95
+26.15(+6.38%)
Market Cap₹969.98 Cr
PE Ratio46.73
IndustryHealthcare
Company Performance:
1D+6.38%
1M+7.23%
6M+27.92%
1Y+56.48%
5Y+316.58%
View Company Insightsright
More news about Sakar Healthcare
16Jul 25
Sakar Healthcare Expands European Footprint with New Anti-Cancer Injection Approvals
Sakar Healthcare Ltd. has obtained its third and fourth marketing authorizations for oncology injections in the European market. The company is now preparing for commercial supply of these newly approved products, potentially opening up new revenue streams and strengthening its position in the oncology sector. This expansion into the European market with specialized oncology products is expected to diversify the company's market presence, offer revenue growth potential, and enhance its global standing in the pharmaceutical industry.
 no imag found
18Jun 25
Sakar Healthcare Eyes EU Expansion with Anticipated MAS Approval for Oncology Products
Sakar Healthcare Ltd expects to receive Marketing Authorization System (MAS) approval for its oncology products in the European Union (EU) over the coming months. The company has already secured its second marketing authorization for an oncology injection in the EU. These approvals are expected to significantly boost Sakar's export capabilities to the EU market, potentially increasing its global footprint and revenue streams. The gradual approval process reflects the company's strategic focus on the oncology segment and its efforts to expand in the European pharmaceutical market.
 no imag found
15May 25
Sakar Healthcare Reports Impressive Q4 FY23 Results with Substantial Profit Growth
Sakar Healthcare Ltd has released its Q4 FY23 financial results, showing significant year-over-year improvements. Net profit increased by 87.10% to ₹58.00 crore, while revenue grew by 16.74% to ₹502.00 crore. EBITDA rose by 42.73% to ₹157.00 crore, with the EBITDA margin expanding by 583 basis points to 31.30%. These results demonstrate strong performance across all key financial metrics, indicating robust demand for the company's products and improved operational efficiency.
 no imag found
21Apr 25
Sakar Healthcare Achieves First EU Marketing Authorization for Oncology Injection
Sakar Healthcare Ltd has obtained its first Marketing Authorization (MA) in the European Union for an oncology injection. This approval marks a significant milestone in the company's international expansion, opening up opportunities in the European oncology market. The authorization demonstrates Sakar's ability to meet EU regulatory standards and strengthens its oncology product portfolio.
 no imag found
16Apr 25
Sakar Healthcare Expands Global Reach with 9 New Export Agreements
Sakar Healthcare Ltd has signed nine strategic agreements with partners in Europe and South America for exporting oncology products. This move marks a significant step in the company's global expansion strategy, particularly in the oncology segment. While financial details are undisclosed, the partnerships are expected to boost export volumes and revenue, diversify market presence, and strengthen the company's position in the specialized pharmaceutical market.
 no imag found
Sakar Healthcare
435.95
+26.15
(+6.38%)
1 Year Returns:+56.48%
Industry Peers
Sun Pharmaceutical
1,704.40
(0.0%)
Divis Laboratories
6,134.00
(+1.31%)
Torrent Pharmaceuticals
3,980.90
(-1.06%)
Cipla
1,333.90
(+0.54%)
Dr Reddys Laboratories
1,247.00
(+0.55%)
Lupin
2,211.50
(+0.74%)
Zydus Life Science
907.60
(+0.26%)
Mankind Pharma
2,090.00
(+0.03%)
Aurobindo Pharma
1,179.90
(-2.70%)
Alkem Laboratories
5,669.50
(+0.28%)